ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KPRX vs LEXX // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Kiora Pharmaceuticals Inc. (NASDAQ) VS. Lexaria Bioscience Corp. (NASDAQ) • 15-METRIC TALLY: KPRX 0 — LEXX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KPRX VS. LEXX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KPRX LEXX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 52.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 4/9 -3.00 LEXX /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 29.1 52.4 -23.30 LEXX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $7.8M $7.9M -$154.7K LEXX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KPRX REV LEXX REV KPRX GROSS % LEXX GROSS % KPRX FCF LEXX FCF
FY 2025 $0 $705.9K — 98.0% -$10.1M -$10.5M
FY 2024 $16.0M $464.3K — 98.0% $8.6M -$5.0M
FY 2023 $0 $226.2K — — -$9.6M -$5.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KPRX // BETA —
LEXX // BETA —